Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Rating) shares crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.10 and traded as high as $4.18. Ocular Therapeutix shares last traded at $4.11, with a volume of 439,524 shares.
Analysts Set New Price Targets
Several equities analysts recently weighed in on OCUL shares. StockNews.com cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Friday, November 11th. HC Wainwright dropped their target price on Ocular Therapeutix from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, November 8th. JMP Securities dropped their price target on Ocular Therapeutix from $25.00 to $12.00 and set a “market outperform” rating for the company in a research note on Monday, January 9th. Finally, Raymond James dropped their price target on Ocular Therapeutix from $29.00 to $14.00 and set a “strong-buy” rating for the company in a research note on Tuesday, November 8th.
Ocular Therapeutix Stock Performance
The company has a quick ratio of 4.92, a current ratio of 4.98 and a debt-to-equity ratio of 1.15. The company has a 50 day simple moving average of $3.10 and a 200-day simple moving average of $4.12. The stock has a market capitalization of $316.51 million, a price-to-earnings ratio of -4.07 and a beta of 1.34.
Insiders Place Their Bets
In other Ocular Therapeutix news, major shareholder Summer Road Llc bought 7,328 shares of the business’s stock in a transaction on Monday, November 7th. The stock was purchased at an average price of $3.50 per share, for a total transaction of $25,648.00. Following the completion of the transaction, the insider now directly owns 6,122,089 shares of the company’s stock, valued at $21,427,311.50. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.80% of the company’s stock.
Hedge Funds Weigh In On Ocular Therapeutix
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cetera Advisors LLC boosted its position in Ocular Therapeutix by 4.3% during the second quarter. Cetera Advisors LLC now owns 49,584 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 2,040 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in Ocular Therapeutix by 13.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 34,873 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 4,045 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Ocular Therapeutix by 19.2% during the third quarter. Price T Rowe Associates Inc. MD now owns 30,889 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 4,981 shares during the period. SG Americas Securities LLC boosted its position in shares of Ocular Therapeutix by 51.4% in the third quarter. SG Americas Securities LLC now owns 15,285 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 5,191 shares during the period. Finally, Algert Global LLC boosted its position in shares of Ocular Therapeutix by 7.8% in the third quarter. Algert Global LLC now owns 73,590 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 5,310 shares during the period. Institutional investors own 55.40% of the company’s stock.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
- Get a free copy of the StockNews.com research report on Ocular Therapeutix (OCUL)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.